TISIDB

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Mitochondrion
Domain	PF00106 short chain dehydrogenase
Function	Mitochondrial dehydrogenase that catalyzes the beta-oxidation at position 17 of androgens and estrogens and has 3-alpha-hydroxysteroid dehydrogenase activity with androsterone (PubMed:9553139, PubMed:23042678, PubMed:12917011, PubMed:18996107, PubMed:25925575, PubMed:28888424). Catalyzes the third step in the beta-oxidation of fatty acids (PubMed:9553139, PubMed:12917011, PubMed:18996107, PubMed:25925575, PubMed:28888424). Carries out oxidative conversions of 7-alpha-OH and 7-beta-OH bile acids (PubMed:12917011). Also exhibits 20-beta-OH and 21-OH dehydrogenase activities with C21 steroids (PubMed:12917011). By interacting with intracellular amyloid-beta, it may contribute to the neuronal dysfunction associated with Alzheimer disease (AD) (PubMed:9338779). Essential for structural and functional integrity of mitochondria (PubMed:20077426). ; FUNCTION: In addition to mitochondrial dehydrogenase activity, moonlights as a component of mitochondrial ribonuclease P, a complex that cleaves tRNA molecules in their 5'-ends (PubMed:18984158, PubMed:24549042, PubMed:25925575, PubMed:26950678, PubMed:28888424). Together with HSD17B10/MRPP2, forms a subcomplex of the mitochondrial ribonuclease P, named MRPP1-MRPP2 subcomplex, which displays functions that are independent of the ribonuclease P activity (PubMed:23042678, PubMed:29040705). The MRPP1-MRPP2 subcomplex catalyzes the formation of N(1)-methylguanine and N(1)-methyladenine at position 9 (m1G9 and m1A9, respectively) in tRNAs; HSD17B10/MRPP2 acting as a non-catalytic subunit (PubMed:23042678, PubMed:25925575, PubMed:28888424). The MRPP1-MRPP2 subcomplex also acts as a tRNA maturation platform: following 5'-end cleavage by the mitochondrial ribonuclease P complex, the MRPP1-MRPP2 subcomplex enhances the efficiency of 3'-processing catalyzed by ELAC2, retains the tRNA product after ELAC2 processing and presents the nascent tRNA to the mitochondrial CCA tRNA nucleotidyltransferase TRNT1 enzyme (PubMed:29040705).

> Gene Ontology [ TOP ]
Biological Process	GO:0000959 mitochondrial RNA metabolic process GO:0000963 mitochondrial RNA processing GO:0001510 RNA methylation GO:0006399 tRNA metabolic process GO:0006400 tRNA modification GO:0008033 tRNA processing GO:0009081 branched-chain amino acid metabolic process GO:0009083 branched-chain amino acid catabolic process GO:0009451 RNA modification GO:0016054 organic acid catabolic process GO:0030488 tRNA methylation GO:0032259 methylation GO:0034470 ncRNA processing GO:0043414 macromolecule methylation GO:0044282 small molecule catabolic process GO:0070525 tRNA threonylcarbamoyladenosine metabolic process GO:0070900 mitochondrial tRNA modification GO:0070901 mitochondrial tRNA methylation GO:0090646 mitochondrial tRNA processing GO:1900864 mitochondrial RNA modification GO:1901565 organonitrogen compound catabolic process
Molecular Function	GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity GO:0008709 cholate 7-alpha-dehydrogenase activity GO:0016229 steroid dehydrogenase activity GO:0016614 oxidoreductase activity, acting on CH-OH group of donors GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0030283 testosterone dehydrogenase [NAD(P)] activity GO:0033764 steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0047015 3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity
Cellular Component	GO:0005759 mitochondrial matrix

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00280 Valine, leucine and isoleucine degradation hsa01100 Metabolic pathways
Reactome	R-HSA-70895: Branched-chain amino acid catabolism R-HSA-74160: Gene Expression R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives R-HSA-72312: rRNA processing R-HSA-8868766: rRNA processing in the mitochondrion R-HSA-6787450: tRNA modification in the mitochondrion R-HSA-72306: tRNA processing R-HSA-6785470: tRNA processing in the mitochondrion

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between HSD17B10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of HSD17B10 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -1.83; FDR: 0.04110	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of HSD17B10 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.143	0.603
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.204	0.947
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.102	0.963
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.005	0.988
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.087	0.958
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.119	0.953
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.024	0.946
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.075	0.962
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.136	0.938
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.327	0.876
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.423	0.896
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.072	0.322

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of HSD17B10 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HSD17B10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HSD17B10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HSD17B10. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HSD17B10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of HSD17B10 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between HSD17B10 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	HSD17B10
Name	hydroxysteroid (17-beta) dehydrogenase 10
Aliases	ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal Location	Xp11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting HSD17B10 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting HSD17B10.

ID	Name	Drug Type	Targets	#Targets
DB00157	NADH	Small Molecule	AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......	144
DB02820	1-Azepan-1-Yl-2-Phenyl-2-(4-Thioxo-1,4-Dihydro-Pyrazolo[3,4-D]Pyrimidin-5-Yl)Ethanone Adduct	Small Molecule	HSD17B10	1

Browse HSD17B10